Aditxt, Inc. Signs Non-Binding Letter Of Intent To Acquire A Point-of-Care Diagnostic Technology Development Company; Says The Target ‘holds an exclusive license in U.S. & Canada for at-home and in-office rapid antigen COVID-19 test’
The target holds an exclusive license in U.S. & Canada for at-home and in-office rapid antigen COVID-19 test
EUA application for the COVID-19 rapid antigen test was submitted in September 2021
Target acquisition
Mid-Afternoon Market Update: Dow Rises Over 100 Points; CTI BioPharma Shares Plummet
Toward the end of trading Wednesday, the Dow traded up 0.39% to 34,617.2 while the NASDAQ climbed 0.17% to 15,564.73. The S&P also rose, gaining 0.68% to 4,597.96.
Mid-Day Market Update: Build-A-Bear Jumps After Q3 Results; BeyondSpring Shares Slide
Midway through trading Wednesday, the Dow traded up 1.06% to 34,847.76 while the NASDAQ climbed 1.17% to 15,719.00. The S&P also rose, gaining 1.48% to 4,634.64.
The Daily Biotech Pulse: Adcom Backs Merck’s Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
Here's a roundup of top developments in the biotech space over the last 24 hours: